EGG-CUP

  • Research type

    Research Study

  • Full title

    Enabling Genomic Testing in Cancer of Unknown Primary (EGG-CUP)

  • IRAS ID

    332987

  • Contact name

    Natalie Cook

  • Contact email

    natalie.cook17@nhs.net

  • Sponsor organisation

    The Christie NHS Foundation Trust

  • Duration of Study in the UK

    4 years, 7 months, 12 days

  • Research summary

    Cancers of Unknown Primary (CUP) are an important but historically under-researched clinical entity. CUP is the 6th leading cause of cancer death in the UK and prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Here we intend to focus only the North West to ensure we can facilitate and establish pathways across the region.

    Precision medicine has transformed treatment strategies in known tumour types however in CUP there remains an urgent need to better understand CUP molecular characteristics to establish potential roles for novel therapeutic strategies. Treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. Access to good quality tissue for molecular profiling remains a huge challenge in CUP. The emergence of liquid biopsies (sequence DNA in a blood test) as a source of biomarkers is also gaining rapid ground and this research aims to explore the potential utility of liquid biopsies in CUP.

    Here, we plan to offer liquid biopsies to approximately 100 patients. Based upon the molecular changes we will determine if there is a specific cancer type and identify actionable molecular changes.

    The NHS Genomic Medicine Service are supportive of this research. We will incorporate genomic findings into standard of care discussions through NHS genomic laboratory hubs. This study will feed into the NHS Genomics Medicines Service via the North-West Genomics laboratories. The genomic and clinical data that will be collected could be used to drive additional research in the UK. It would address an area of high unmet need and has the potential to change clinical care.

  • REC name

    North West - Haydock Research Ethics Committee

  • REC reference

    24/NW/0181

  • Date of REC Opinion

    28 Jun 2024

  • REC opinion

    Further Information Favourable Opinion